Person: KARAALP, ATİLA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARAALP
First Name
ATİLA
Name
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only In vitro contractile responses of human detrusor smooth muscle to oxytocin: does it really have effect?(TAYLOR & FRANCIS LTD, 2020) KARAALP, ATİLA; Tarhan, Fatih; Duman, Nesrin Caglayan; Ozkula, Songul; Karaalp, Atila; Canguven, OnderBackground and objectives: The aim of this study was to investigate the contractile effects of oxytocin (OT) in human detrusor muscle in in vitro conditions. Material and Methods: Human detrusor muscle samples were obtained from seven patients that undergone radical cystectomy. Four female Wistar rats' uterine samples were used as control. Contractile responses were tested of carbachol in organ bath. Cumulative concentration response curves were constructed to OT and then the strips were incubated with atosiban (OT antagonist) and a second concentration response curve to OT were constructed. Results: Carbachol, contracted all human strips for the functionality test whereas OT in any concentrations did not produce significant contraction on all human strips. In only one bladder strip and in a very high concentration slight contraction was recorded. Moreover no contractile response was recorded in any OT concentrations in the presence of atosiban. The rat uterine strips responded to OT in a dose dependent manner. Atosiban, the OT receptor antagonist diminished totally those contractile responses. Conclusion: It is been demonstrated here that there is no contractile response to OT in human detrusor muscle. These findings should be supported by further investigations determining the presence of the OT receptor in human detrusor.Publication Open Access Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis(2022-03-01) KARAALP, ATİLA; SÜSLEYİCİ, BELGİN; Cevik M., Namal E., Iner-Koksal U., Dinc-Sener N., KARAALP A., Ciftci C., SÜSLEYİCİ B.Background Programmed Cell Death-1 (PD-1) together with Programmed Death Ligand 1 (PDL-1) have crucial roles in anti-tumor immune response, cancer susceptibility and prognosis. Since PD-1 and PDL-1 have been considered as important genetic risk factors in cancer development and their functions can be affected by polymorphic sites, we investigated the effects of PD-1 rs2227981, rs2227982, rs36084323 and PDL-1 rs2282055, rs822336 gene polymorphisms on colorectal cancer (CRC) risk and prognosis in Turkish subjects. Methods and results Our study group consisted of 5-FU or Capacitabine prescribed CRC diagnosed patients and healthy controls. Genotype analyses of PD1 and PDL-1 polymorphisms were performed with Agena MassARRAY platform. rs36084323 CT genotype frequency was found to be higher in controls compared to cases (p C polymorphism might be useful in predicting CRC prognosis. PDL-1 rs2282055 T > G polymorphism might be useful in predicting both CRC risk and prognosis. Further studies should be conducted in larger and different populations to clear the roles of PD-1 and PDL-1 polymorphisms in CRC risk and prognosis.Publication Metadata only Cyp3a4 *1b gene polymorphism in coronary artery disease patients with obesity undergoing statin treatment(Bentham Science Publishers, 2021) KARAALP, ATİLA; Gezer E., Cevik M., Akdeniz C.S., Canbolat I.P., Yurdakul S., Sunbul M., Cagatay P., Deliorman G., Karaalp A., Ciftci C., Sus-Leyici B.Objective: Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality worldwide and statins are frequently prescribed in the treatment of CAD to help lower blood cholesterol levels. Since the main enzyme involved in the metabolism of statins is CYP3A4, we aimed to investigate the effect of CYP3A4 * 1B genotypes on plasma lipid profile in Turkish cardiovascular disease subjects with and without obesity taking statin. Materials and Methods: The study group consisted of 85 cardiovascular disease patients who were prescribed statins and had routine biochemical analysis data. Polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP) assay was performed for genotyping of CYP3A4 *1B (rs2740574) polymorphism. Results: Genotype distribution of CYP3A4 *1B polymorphism was found for homozygous wild (AA) and homozygous polymorphic (GG) genotypes as 94.1% and 5.9%, respectively. We did not detect patients with heterozygous genotype in our study group. We found that the mean LDL-c, TG and TC levels were higher in patients with CYP3A4 *1B GG compared to the AA genotype. The frequency of CYP3A4 *1B GG genotype frequency (9.5%) was detected higher in the obese patients compared to the non-obese patients (7.7%) (χ2=0.037, p=0.85). Conclusion: Our results demonstrate that CYP3A4 *1B homozygous polymorphic genotype distribution tends to be higher in obese patients compared to non-obese patients with cardiovascular disease which may point to *1B allele having a slight effect on serum lipids during statin therapy. Ad-ditional studies with higher samples are needed for evaluating the role of CYP3A4 *1B on lipids in patients under statin therapy. © 2021 Bentham Science Publishers.Publication Metadata only Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis(SPRINGER, 2022) KARAALP, ATİLA; Cevik, Mehtap; Namal, Esat; Iner-Koksal, Ulkuhan; Dinc-Sener, Nur; Karaalp, Atila; Ciftci, Cavlan; Susleyici, BelginBackground Programmed Cell Death-1 (PD-1) together with Programmed Death Ligand 1 (PDL-1) have crucial roles in anti-tumor immune response, cancer susceptibility and prognosis. Since PD-1 and PDL-1 have been considered as important genetic risk factors in cancer development and their functions can be affected by polymorphic sites, we investigated the effects of PD-1 rs2227981, rs2227982, rs36084323 and PDL-1 rs2282055, rs822336 gene polymorphisms on colorectal cancer (CRC) risk and prognosis in Turkish subjects. Methods and results Our study group consisted of 5-FU or Capacitabine prescribed CRC diagnosed patients and healthy controls. Genotype analyses of PD1 and PDL-1 polymorphisms were performed with Agena MassARRAY platform. rs36084323 CT genotype frequency was found to be higher in controls compared to cases (p < 0.001). rs36084323 CT genotype was highly associated with reduced CRC risk compared to CC genotype (OR 0.068, 95% CI 0.022-0.211, p < 0.001). In adjusted analysis, rs2282055 GG genotype was found to be associated with reduced CRC risk (OR 0.271, 95% CI 0.078-0.940, p = 0.040). rs2282055 TT genotype was found to be related to longer progression-free (Bonferroni corrected Log rank p = 0.013) and overall survival (Bonferroni corrected Log rank p = 0.009) to that of GG genotypes. Patients with rs822336 GC+CC genotypes showed longer overall survival times compared to GG (Log rank p = 0.044). Conclusions According to our results, PD-1 rs822336 G > C polymorphism might be useful in predicting CRC prognosis. PDL-1 rs2282055 T > G polymorphism might be useful in predicting both CRC risk and prognosis. Further studies should be conducted in larger and different populations to clear the roles of PD-1 and PDL-1 polymorphisms in CRC risk and prognosis.Publication Metadata only Warfarin pharmacogenetics in patients with heart valve replacement(ELSEVIER, 2020) KARAALP, ATİLA; Bezci, Kivanc; Cevik, Mehtap; Akdeniz, Cansu Selcan; Canbolat, Ismail Polat; Yurdakul, Selen; Sunbul, Murat; Atas, Halil; Cagatay, Penbe; Ciftci, Cavlan; Karaalp, Atila; Susleyici, BelginBackground: Warfarin treatment is crucial to prevent thrombolytic complications after the heart valve replacement (HVR) operation. Our purpose was to investigate the prevalence of CYP2C9 *2 and *3 gene polymorphisms, which are essential in warfarin metabolism in patients with and without HVR surgery prescribed with warfarin. Material and method: 47 patients with and without HVR were genotyped for the CYP2C9*2 (rs1799853, 430 C> T), CYP2C9*3 (rs1057910, 1075 A> C) polymorphisms by PCR-RFLP assay. Results: Homozygous wild (CC), heterozygous and homozygous polymorphic (CT+TT) genotype frequencies of CYP2C9 *2 were determined respectively as 69.6% and 30.4% for patients with HVR; 79.2% and 20.8% for patients without HVR. Homozygous wild (AA) and heterozygous (AC) genotype frequencies of CYP2C9 *3 polymorphism were determined respectively as 73.9% and 26.1%f for patients with HVR; 79.2% and 20.8% for patients without HVR. CYP2C9 *2 and *3 genotype frequencies did not show any statistically significant difference between with and without HVR groups. Conclusion: In the present study, no significant difference was observed between patients with and without HVR with respect to CYP 2C9 *2 and *3 gene polymorphisms in Turkish subjects. Further studies with higher number of patients are needed to evaluate the importance of CYP 2C9 *2 and *3 pharmacogenetic testing in patients with HVR using warfarin.Publication Metadata only The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients(FUTURE MEDICINE LTD, 2020) KARAALP, ATİLA; Akdeniz, Cansu Selcan; Cevik, Mehtap; Canbolat, Ismail Polat; Yurdakul, Selen; Cagatay, Penbe; Ciftci, Cavlan; Karaalp, Atila; Susleyici, BelginAim: Our aim was to examine the effect of CYP2C9 and VKORC1 polymorphisms on warfarin dose requirements in Turkish patients. Materials & methods: 24 warfarin prescribed patients were included and analyzed for eight VKORC1 and 6 CYP2C9 polymorphisms in the study. Results: Patients with CYP2C9 *1/*1 and VKORC1 -1639 GG and GA genotypes required higher warfarin doses in comparison to wild type VKORC1 genotype. Patients with CYP2C9 *1/*3 and VKORC1 -1639 GG genotypes simultaneously, required the lowest dose of warfarin (4.64 mg/day). Patients with CYP2C9 *1/*1 and VKORC1 9041 AA genotype were found to require higher warfarin doses. Conclusion: Our results provide additional evidence to support the hypothesis that CYP2C9 *2, *3, VKORC1 9041 G > A polymorphisms explain considerable proportion of inter-individual variability in warfarin dose requirement.Publication Metadata only Herbal product use patterns and possible herb-drug interactions among older adults in Turkey(ELSEVIER GMBH, 2021) KARAALP, ATİLA; Taneri, Petek Eylul; Akis, Nalan; Karaalp, AtilaBackground: Traditional and Complementary medicine use is on the increase universally. In this descriptive study, the aim is to evaluate the frequency and determinants of herbal product use, as well as determine possible drug-herb interactions among older individuals who live in rural and urban areas. Methods: The study was carried out with individuals 65 years or older in one urban and five rural neighborhoods in Bursa, Turkey. The data was collected during face-to-face interviews using a questionnaire comprising 43 questions. The participants were asked about the drugs and herb/herbal products they use and then the possible drug-herb interactions were evaluated using Micromedex (R). Results: Among the participants, 82.2 % reported using at least one drug regularly, and 18.3 % used at least one herb/herbal product in the past year (rural 26.1 %, urban 13.4 %). Most commonly used herb/herbal products were plane tree leaves and black cumin. Herbal product use was seen more among those experiencing difficulties accessing health care and living alone. Among those using drug and herb/herbal products concurrently, the possible drug-herb interaction rate was 7.5 %. Conclusions: Physicians providing health care services to geriatric populations should inquire about usage of drugs and herbs. Conventional medicine should be made accessible to every older adult, and it should be ensured that they do not have to resort to complementary therapies that could harm their health.